The fight against drug-resistant bacteria marches forward as Adaptive Phage earns $40M+ Series B

A company working toward the field of bacteriophages, developing therapies that use bacteria-killing viruses, just pulled in a significant amount of new capital.

Adaptive Phage Therapeutics closed a $40.75 million Series B, the Gaithersburg, MD-based biotech announced Tuesday morning. The financing was led by Deerfield Management with participation from the Mayo Clinic, which had been a previous investor.